Prescription Medicines
Megaspen Tab.
- Product Category
- Analgesics, Antipyretics & Anti-inflammatory Medicines
- Active Ingredients
- Tramadol hydrochloride, acetaminophen
- Appearance
- Light yellow, oblong, film-coated tablets
- Reimbursement Code
- 648102530
01 / 02
1. Composition and Strength
- Active ingredient: Tramadol hydrochloride (KP)----37.5mg
Acetaminophen (KP)----325mg
- Additives: Powdered cellulose, magnesium stearate, Opadry yellow (310B620001), corn starch, sodium starch glycolate, gelatinized starch, povidone K30
2. Effectiveness
Moderate-severe acute and chronic pain
3. Dosage and dosage
Children and adults over 12 years of age:
The dosage is adjusted according to the patient's pain level and response to treatment.
It is recommended to administer 2 tablets as the initial dose, and the interval between subsequent doses should be at least 6 hours, but should not exceed 8 tablets per day.
Administer the lowest effective dose for as short a period of time as possible.
Do not administer this drug for a longer period of time than necessary. If long-term administration is necessary due to the nature or severity of the disease, conduct regular monitoring to check whether this drug should be continued.
old man
Administer the usual adult dose. However, when tramadol is administered orally to the elderly over 75 years of age, the elimination half-life of tramadol increases by 17%, so this drug should be administered at intervals of at least 6 hours.
renal failure patient
For patients with moderate renal failure (creatinine clearance of 10-30ml/min), the administration interval should be extended to 12 hours.
Administration is not recommended for patients with severe renal failure (creatinine clearance less than 10 ml/min).
Because tramadol is eliminated very slowly during hemodialysis and filtration, there is no need to re-administer this drug to maintain the analgesic effect after dialysis.
liver failure patient
For patients with moderate liver failure, extended administration intervals should be carefully considered.
This drug should not be administered to patients with severe liver failure.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this drug, it may cause liver damage.
2) In very rare cases, serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported in patients taking acetaminophen, and these serious skin reactions can be fatal. Therefore, patients should be fully informed of the signs of such serious skin reactions, and if skin rash or other signs of hypersensitivity appear after taking this drug, they should immediately stop taking it.
3) Seizures have been reported in patients receiving tramadol within the recommended dose range, and the risk of seizures has been shown to increase when doses exceeding the recommended dose are administered.
The risk of seizures increases when tramadol is combined with the following drugs:
- Selective serotonin reuptake inhibitors (SSRI antidepressants or appetite suppressants)
- Tricyclic antidepressants (TCAs) and other tricyclic drugs (e.g. cyclobenzaprine, promethazine, etc.)
- Other drugs
Tramadol may increase the risk of seizures when combined with the following drugs:
- MAO (Monoamine Oxidase) inhibitor
- Neuroleptics
- Drugs that can lower the seizure threshold
The risk of developing convulsions may be increased in patients with epilepsy, those with a history of seizures, or those with risk factors for seizures (head injury, metabolic disorders, patients with alcohol or drug withdrawal, central nervous system infections).
4) Rarely fatal anaphylactoid reactions have been reported in patients receiving tramadol.
5) Treating patients with acute and severe bronchial asthma with narcotic analgesics increases the risk of life-threatening respiratory depression. When administering this drug to this patient group, it must be administered in a place where monitoring is possible or cardiopulmonary resuscitation equipment is available.
Caution should be exercised when administering this drug to patients at risk of respiratory depression, and use of other non-narcotic analgesics should be considered.
6) Concurrent administration of tramadol and central nervous system depressants, including alcohol or benzodiazepine drugs, may cause deep sedation, respiratory depression, coma, and death. Because of these risks, co-administration of this drug and central nervous system depressants should be prescribed only for patients for whom there are no appropriate alternative treatments. If co-administration of this drug and a central nervous system depressant is decided, prescribe it at the lowest effective dose for the shortest period of time and closely monitor the patient for signs and symptoms of respiratory depression and sedation.
7) Administration of this drug to patients with increased intracranial pressure or head injury may cause serious symptoms due to carbon dioxide retention and a secondary increase in cerebrospinal fluid pressure due to the respiratory depressant effect of narcotic analgesics.
8) Tramadol can cause mental and physical dependence of morphine type (μ-opioid).
9) Hepatotoxicity: This drug contains acetaminophen and tramadol. Acetaminophen has been associated with acute liver failure, sometimes resulting in liver transplantation and death, and most liver damage has been associated with doses exceeding 4,000 milligrams per day taken with other acetaminophen products, so use with caution. In particular, patients with liver impairment must consult with their doctor before taking this medication.
10) Patients who are CYP2D6 ultra-fast metabolizers can metabolize tramadol to its active metabolite (M1) more quickly and completely than other patients. This rapid metabolism may result in higher than expected serum M1 concentrations, which may increase the risk of respiratory depression. For patients known to be CYP2D6 ultrarapid metabolizers, alternative agents, dose reduction, and/or increased frequency of monitoring for signs of tramadol overdose (e.g., respiratory depression) are recommended. Even at the recommended dose of this drug, ultra-rapid metabolizers may experience life-threatening or fatal respiratory depression or other symptoms during overdose (see 10. Treatment in case of overdose - 1) Tramadol).
11) Ultra-rapid metabolism of tramadol and another risk factor for life-threatening respiratory depression in children: Life-threatening respiratory depression and death have occurred in children administered tramadol. Some reported cases occurred after children underwent tonsillectomy and/or adenoidectomy and were demonstrated to be ultra-rapid metabolizers of tramadol due to CYP2D6 polymorphism. This drug is not administered to children under 12 years of age and children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy. This drug should be avoided in children 12 to 18 years of age who have other risk factors that increase susceptibility to the respiratory depressant effects of tramadol.
12) This drug may cause sleep apnea syndrome (including central sleep apnea) and hypoxia (including sleep-related hypoxia), and the risk of occurrence increases in a dose-dependent manner. It is necessary to continuously evaluate whether sleep apnea occurs or existing symptoms worsen, and in this case, gradually reducing or discontinuing the drug dose should be considered.
13) Hyponatremia has been reported very rarely when using this drug, and is generally reported in patients with vulnerable risk factors such as the elderly and/or those taking drugs that may cause hyponatremia. In some reports, this hyponatremia has been shown to be the result of syndrome of dysdiuretic hormone secretion (SIADH) and is reversible with discontinuation of this drug and appropriate treatment (e.g. fluid restriction). Monitoring for signs and symptoms of hyponatremia during treatment with this drug is recommended for patients with predisposed risk factors.
2. Do not administer to the following patients
1) Patients with hypersensitivity to the ingredients of this drug
2) Patients addicted to drugs that act on the central nervous system, such as alcohol, sleeping pills, centrally acting analgesics, narcotic analgesics, or psychotropic drugs
3) Patients with severe respiratory depression (mild respiratory depression may occur)
4) Patients at risk of clouding of consciousness due to head injury or brain lesion
5) Patients receiving MAO inhibitors or patients who have taken the medication within the last 14 days
6) Patients with peptic ulcers and severe blood abnormalities
7) Patients with severe hepatic impairment, severe renal impairment, or severe cardiac dysfunction
8) Nursing mothers
9) Children under 12 years of age
10) Post-operative management in children under 18 years of age who underwent tonsillectomy and/or adenoidectomy.
11) Patients with aspirin asthma (asthma attacks caused by non-steroidal anti-inflammatory drugs) or a history of it
12) Acute and severe bronchial asthma patients in places without monitoring equipment or cardiopulmonary resuscitation equipment
13) Patients with epilepsy not controlled by medication
3. Administer with caution to the following patients:
1) Patients taking concurrent or repeated administration of morphine (a mild antagonistic effect of morphine was recognized in animal experiments, so withdrawal symptoms may occur).
2) Patients taking central nervous system depressants such as narcotic analgesics, anesthetics, hypnotics, phenothiazines, tranquilizers, sedatives, etc.
3) Patients with biliary disease (in animal experiments, when administered in large quantities, the sphincter of Oddi contracted.)
4) Patients with hepatic impairment (in animal experiments, serum GOT and GPT activity levels may be elevated.)
5) Patients with renal impairment
6) Drunk patient
7) Patients with hypersensitivity to narcotic analgesics
8) Patients with epilepsy or those likely to have seizures
9) Patients in shock or changes in consciousness due to unknown causes
4. Adverse reactions
4.1 Clinical trial data
1) Adverse reactions reported at a rate of more than 1% in the group administered this drug during placebo-controlled clinical trials of this drug
* Refer to manual for table details
2) Adverse reactions reported at a rate of less than 1% in the group administered this drug during placebo-controlled clinical trials of this drug
* Refer to manual for table details
3) Adverse reactions confirmed in clinical trials/post-marketing surveillance of tramadol
* Refer to manual for table details
4) Regarding adverse reactions identified in clinical trials/post-marketing surveillance of acetaminophen, allergic reactions (mainly skin rash) or secondary hypersensitivity reactions to acetaminophen were rarely reported, but generally recovered after discontinuation of drug administration, and symptomatic treatment was administered when necessary. Blood disorders, including thrombocytopenia and agranulocytosis, have been reported but not necessarily related to acetaminophen. There are several reports indicating that acetaminophen may cause hypoprothrombinemia when administered together with warfarin analogues. Cases of metabolic acidosis due to pyroglutamic acidosis (HAGMA) have been reported in patients with risk factors who use acetaminophen.
4.2. Adverse reactions after marketing
1) The following post-marketing adverse reactions were confirmed: hyponatremia/antidiuretic hormone secretion syndrome, fixed eruption.
2) As a result of a post-marketing survey conducted on 37,967 patients over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 4.57% (1,737/37,967, 2,501 cases) regardless of causal relationship with the drug. The most common adverse reactions were digestive system adverse reactions such as nausea, constipation, and vomiting (1,391 cases (3.66%)), nervous system adverse events such as dizziness and headache (563 cases (1.48%)), systemic abnormalities (149 cases (0.39%)), mental abnormalities (149 cases (0.39%)), skin and appendages (105 cases (0.28%)), and blood system adverse reactions (105 cases). 31 cases (0.08%), kidney and urinary system 28 cases (0.07%), circulatory system 28 cases (0.07%), respiratory system 21 cases (0.06%), cardiovascular system 1 case and other 43 cases (0.11%).
The incidence of adverse drug reactions for which a causal relationship with this drug could not be ruled out was 4.14% (1,573 people/37,967 people, 2,244 cases). The main adverse drug reactions are nausea 1.49% (567 people/37,967 people) and dizziness 0.95% (358 people/37,967 people). Other adverse reactions reported in less than 1% are classified by institution as follows.
(1) Systemic abnormalities: asthenia, fatigue, fever, edema, chest pain, stiffness, syncope
(2) Cardiovascular system: congestive heart failure
(3) Nervous system: Dizziness, headache, vertigo, stupor, migraine, tremor, paresthesia, hypertonia, worsening migraine, involuntary muscle contraction, convulsions.
(4) Respiratory system: dyspnea, asthma, dyspnea on exertion, cough, bronchitis
(5) Kidney and urinary system: urinary disorders, urinary retention, frequent urination, abnormal kidney function levels, oliguria
(6) Skin and appendages: pruritus, rash, increased sweating, urticaria
(7) Digestive system: nausea, vomiting, indigestion, abdominal pain, constipation, dry mouth, diarrhea, dysphagia, fart, tongue edema, increased saliva, rectal cancer progression, esophageal cancer progression, stomach cancer progression, paralytic ileus, hiccups, cholecystitis
(8) Mental system: drowsiness, insomnia, loss of appetite, anxiety, depression, nervousness, emotional instability, hallucinations, depersonalization
(9) Blood system: anemia, decreased hemoglobin, decreased red blood cells, decreased white blood cells, increased white blood cells, decreased platelets
(10) Circulatory system: palpitations, hypertension, arrhythmia, tachycardia, worsening hypertension, aortic stenosis
(11) Others: bleeding, increased cholesterol, weight loss, tinnitus, chills, buttock pain, thigh pain, allergic rhinitis, epistaxis, abnormal vision, progression of biliary tract cancer, foreign body sensation in the eyes, progression of liver cancer, abnormal liver function
Serious adverse drug reactions included one case each of liver dysfunction, cholecystitis, paralytic ileus, and stupor, and one case each of unexpected drug adverse reactions included cholecystitis, hiccups, paralytic ileus, abnormal kidney function levels (elevated BUN/CR), increased saliva, and bleeding.
In a survey targeting patients with renal impairment, a special type of patient, the occurrence rate of adverse drug reactions was 6.25% (11/176, 165 cases), and the main adverse drug reactions were nausea and dizziness, 4 cases each (2.27%). There were no serious adverse drug reactions or unexpected adverse reactions. In a survey targeting patients with liver impairment, a special type of patient, the incidence of adverse drug reactions was 6.63% (22/332, 36 cases), and the main adverse drug reactions were nausea in 12 cases (3.61%) and dizziness in 6 cases (1.81%). The serious adverse drug reactions were one case each of paralytic ileus, cholecystitis, and liver dysfunction (0.30%), and the unexpected adverse reactions were one case each of paralytic ileus and cholecystitis.
3) Serious adverse reactions reported voluntarily during the domestic post-marketing surveillance period were 3 cases of nausea, 2 cases each of vertigo and dyspnea, stupor, migraine, speech impediment, loss of consciousness, recurrence of myocardial infarction, hypotension, vomiting, dyspepsia, confusion, multiple organ failure, anaphylaxis, and intentional overdose, for a total of 23 cases. Since these were reported from a population of uncertain size, the frequency and causal relationship of this drug must be confirmed. It's difficult to estimate.
4) In addition, during the domestic post-marketing surveillance period, as a result of a separate post-marketing clinical trial conducted on a total of 5,566 people in addition to the use result survey, a total of 3 cases of unexpected adverse drug reactions were reported, 2 cases of belching (0.04%) and 1 case of chest discomfort (0.02%).
5) Patients who had a history of taking therapeutic drugs (painkillers) before administering this drug had a statistically significantly higher rate of adverse reactions compared to those who had no history of taking medication (5.92% vs 3.75%, p<0.001)). In addition, the adverse reaction rate in the subjects of investigation whose average daily dose was 4 or more tablets was 8.35% (289/3460 people), which was statistically significantly higher than the 4.36% (1325/30419 people) in the patient group who took 2 or more but less than 4 tablets (p<0.001).
5. General precautions
1) Do not administer in excess of the recommended dose, and do not administer in combination with other tramadol or acetaminophen products.
2) This medicine contains tramadol as its main ingredient. Part of the analgesic effect of this drug is due to the binding of tramadol, the main ingredient of this drug, to mu-opioid receptors. Repeated administration of narcotic analgesics, even at recommended doses, may result in intolerance, physical dependence, and psychological dependence. Before prescribing this medication, the patient's risk for dependence and abuse of opioids should be assessed, and all patients receiving this medication should be monitored for the development of such behaviors. The risk is increased in patients with a history or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). This drug should not be used in patients dependent on narcotic analgesics. In some patients who were previously dependent on other narcotic analgesics, tramadol has been associated with relapse of physical dependence. Patients at risk of drug abuse or dependence should be observed carefully and administered for a short period of time. Tramadol is not appropriate as an alternative medication for patients dependent on narcotic analgesics and does not suppress the withdrawal symptoms of opiate drugs or morphine. Concomitant use with opioid agonists-antagonists (nalbuphine, buprenorphine, pentazocine) is not recommended because there is a risk of reduced analgesic effect and withdrawal symptoms due to competitive blocking effect at the receptor.
3) If you suddenly stop taking this drug, withdrawal symptoms such as anxiety, sweating, insomnia, stiffness, pain, nausea, tremor, diarrhea, upper respiratory syndrome, piloerection, excitement, nervousness, hyperkinesia, and gastrointestinal symptoms may appear. Panic attacks, severe anxiety, hallucinations, paresthesias, tinnitus, and abnormal central nervous system reactions have also been reported very rarely. Clinical experience shows that withdrawal symptoms can be alleviated if the drug dose is reduced and discontinued.
4) In patients receiving tramadol, allergic reactions such as urticaria, rash, bronchospasm, toxic skin necrosis, and Stevenson-Johnson syndrome, including rare but serious and fatal anaphylactic reactions, have been reported. This drug should not be administered to patients with a history of anaphylactoid reactions to codeine and other narcotic analgesics because the risk may be increased. Patients are advised to seek medical help immediately if symptoms of hypersensitivity appear.
5) Convulsions have been reported when tramadol is administered to patients taking other drugs with the potential for seizures or lowering the seizure threshold, especially selective serotonin reuptake inhibitors, tricyclic antidepressants, antipsychotics, centrally acting analgesics, or local anesthetics. Patients with epilepsy controlled with medication or patients with the possibility of epilepsy should be administered this drug only when absolutely necessary.
6) Excessive acetaminophen administration to chronic alcoholics may increase liver toxicity. Administration of this drug to patients with hepatic impairment is not recommended.
7) The pharmacokinetics and tolerability of this drug have not been tested in patients with liver dysfunction. Tramadol and acetaminophen are metabolized primarily in the liver. Patients with severe hepatic impairment are not recommended to use this drug.
8) The combination of tramadol and acetaminophen has not been tested in patients with renal failure. Experience with the use of tramadol may reduce the extent and rate of excretion of tramadol and its active metabolite M1 in patients with renal insufficiency. For patients with a creatinine clearance of less than 30 mL/min, the dosing interval should not exceed 2 tablets every 12 hours.
9) When tramadol is administered long-term, it is difficult to completely exclude the possibility of dependence, so the administration period must be adjusted or a temporary withdrawal period must be taken.
10) In one study, it was reported that when tramadol was used during general anesthesia with enfluorene and nitric oxide, the number of cases of anesthesia weakening during surgery increased. Until further information is available, use of tramadol during mild-level anesthesia should be avoided.
11) Caution should be exercised when administering this drug to patients taking selective serotonin reuptake inhibitors. The risk of adverse reactions, including seizures and serotonin syndrome, increases when tramadol is combined with selective serotonin reuptake inhibitors.
12) Life-threatening respiratory depression and death occurred in children administered tramadol. Tramadol and codeine are subject to metabolic variability based on CYP2D6 genotype, which may increase exposure to active metabolites. Post-marketing reports on tramadol or codeine suggest that children under 12 years of age may be susceptible to the respiratory depressant effects of tramadol. Children with obstructive sleep apnea who are treated with opioids for pain, especially after tonsillectomy and/or adenoidectomy, may be sensitive to respiratory depressant effects. The risk for life-threatening respiratory depression and death is as follows:
(1) This drug is not administered to children under 12 years of age.
(2) This drug is not administered for post-operative management to children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy.
(3) Avoid administering this drug to adolescents aged 12 to 18 years who have other risk factors that increase sensitivity to the respiratory depressant effects of tramadol, except in cases where the benefits are judged to outweigh the risks. Risk factors include conditions associated with respiratory depression, such as postoperative conditions, obstructive sleep apnea, obesity, significant pulmonary disease, neuromuscular disease, and concomitant use of other drugs that cause respiratory depression.
(4) When prescribing opioids to children, like adults, health care professionals should administer the lowest effective dose for the shortest period of time and inform patients, guardians, and caregivers about the symptoms and risks of opioid overdose.
13) Serious, life-threatening, or fatal cases in patients receiving recommended doses of tramadol.
Respiratory depression has been reported. If it is not recognized and treated promptly, it may lead to respiratory arrest and death. Management may include close observation of associated symptoms and the use of an opioid antagonist; symptoms should be treated appropriately according to the patient’s clinical condition. Carbon dioxide retention caused by respiratory depression after taking this medicine may intensify signs and symptoms of sedation.
14) Tramadol is subject to polymorphic metabolism, like codeine, in ultra-rapid metabolizers of CYP2D6 substrates exposed to potentially life-threatening levels of M1. At least one death has been reported in a nursing infant exposed to high levels of morphine in breast milk due to the mother being an extremely rapid metabolizer of codeine. Nursing infants whose mothers were ultrarapid metabolizers who administered this drug may have been exposed to potentially high levels of M1 and experienced life-threatening respiratory depression.
15) Opioid analgesics can sometimes cause reversible adrenal insufficiency requiring careful monitoring and glucocorticoid replacement therapy. Symptoms of acute or chronic adrenal insufficiency include severe abdominal pain, nausea, vomiting, low blood pressure, extreme fatigue, loss of appetite, and weight loss.
15) This drug may cause opioid-induced hyperalgesia. Symptoms of opioid-induced hyperalgesia include, but are not limited to, increased pain levels with dose increases, decreased pain levels with dose decreases, or pain from stimuli that do not normally cause pain. If a patient develops these symptoms, a dose reduction or change in opioid should be carefully considered.
6. Drug interactions
1) MAO inhibitors (e.g. phenelzine, tranylcypromine, linezolid)
- Mechanism: Drug effects are additive or synergistic.
- Clinical implications: Co-administration of this drug in patients receiving MAO inhibitors or who have taken such drugs within the past 14 days should be contraindicated due to the increased risk of seizures and serotonin syndrome. (Refer to 2. Do not administer to the following patients). Interaction of MAO inhibitors with opioids may result in serotonin syndrome or opioid toxicity.
- Action: Patients who are taking MAO inhibitors or have stopped taking them within 14 days should not use this drug.
2) Serotonergic drugs (e.g. selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptophan, 5-HT3 receptor antagonists, mirtazapine, trazodone, drugs that affect the serotonergic neurotransmission system, cyclobenzaprine, metaxalone back skeletal muscle relaxant)
- Mechanism: Drug effects are additive or synergistic.
- Clinical implications: Combination use of tramadol and serotonergic drugs increases the risk of adverse events, including seizures and serotonin syndrome.
- Measures: When administering this drug to patients taking serotonergic drugs, monitor for signs of adverse reactions and exercise caution. If serotonin syndrome is suspected, discontinue treatment with this drug.
3) CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin)
- Mechanism: CYP3A4 induction increases the metabolic rate of tramadol.
- Clinical Effects: When this drug is co-administered with a CYP3A4 inducer, the blood concentration of tramadol may decrease, which may result in decreased therapeutic effect or development of withdrawal symptoms in patients who are physically dependent on tramadol. After discontinuation of CYP3A4 inducer administration, the effect decreases and blood tramadol concentration increases. This may increase or prolong the therapeutic effect and adverse reactions, and may result in severe respiratory depression, seizures, and serotonin syndrome.
- Action: If co-administration of this drug and a CYP3A4 inducer is necessary, consider increasing the dose of this drug until stable drug effects are achieved.
Monitor patients for signs of opioid withdrawal. If treatment with a CYP3A4 inducer is discontinued, consider reducing the dose and monitor the patient for signs of seizures, serotonin syndrome, sedation, and respiratory depression. When used in combination with carbamazepine, the analgesic effect and duration of action of tramadol may be significantly reduced due to a decrease in the plasma concentration of tramadol. Coadministration is not recommended because carbamazepine increases tramadol metabolism and may increase the risk of tramadol seizures.
4) CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine, amitriptyline, bupropion)
- Mechanism: CYP2D6 inhibition reduces the metabolic rate of tramadol.
- Clinical effects: When this drug is co-administered with a CYP2D6 inhibitor, especially when a CYP2D6 inhibitor is added after a stable dose of this drug is reached, the blood concentration of tramadol may increase and the blood concentration of the metabolite M1 may decrease. Because M1 is a more potent mu-opioid agonist, reduced M1 exposure may reduce therapeutic efficacy in patients with physical dependence to tramadol and may result in signs and symptoms of opioid withdrawal. Increased exposure to tramadol may increase or prolong the therapeutic effect and may increase the risk of serious adverse events such as seizures and serotonin syndrome. After discontinuation of CYP2D6 inhibitor administration, the effect decreases, so the blood tramadol concentration decreases and the blood M1 concentration increases. While this may increase or prolong the therapeutic effect, it may also increase adverse reactions related to opioid toxicity and may potentially cause fatal respiratory depression.
- Action: If co-administration of this drug and a CYP2D6 inhibitor is necessary, closely observe patients for adverse reactions such as opioid withdrawal, seizures, and serotonin syndrome. When treatment with a CYP2D6 inhibitor is discontinued, consider reducing the dose until stable drug effects are achieved. Monitor patients closely for adverse events such as respiratory depression and sedation.
5) CYP3A4 inhibitors (e.g. macrolide antibiotics such as erythromycin, azole antifungals such as ketoconazole, protease inhibitors such as ritonavir)
- Mechanism: CYP3A4 inhibition reduces the metabolic rate of tramadol.
- Clinical implications: Co-administration of this drug with CYP3A4 inhibitors may increase blood concentrations of tramadol and may increase metabolism through CYP2D6 and blood concentrations of M1. After discontinuation of CYP3A4 inhibitors, their effectiveness decreases and blood tramadol concentrations decrease. This may reduce the effects of the opioid and reduce signs and symptoms of opioid withdrawal in patients with physical dependence on tramadol.
- Action: If co-administration of this drug and a CYP3A4 inhibitor is necessary, consider reducing the dose of this drug until stable drug effects are achieved. In particular, when a CYP3A4 inhibitor is added when a stable dose of this drug is reached, patients should be closely monitored for an increased risk of adverse reactions related to opioid toxicity, such as seizures, severe adverse events such as serotonin syndrome, and potentially fatal respiratory depression.
If the CYP3A4 inhibitor is discontinued, consider increasing the dose until stable drug effects are achieved, and monitor the patient for signs and symptoms of opioid withdrawal.
6) Central nervous system depressants such as benzodiazepines and alcohol (e.g. benzodiazepines and other sedative/hypnotics, tranquilizers, muscle relaxants, general anesthetics, other opioids, alcohol)
- Mechanism: Drug effects are additive or synergistic.
- Clinical effects: Concurrent administration of tramadol with central nervous system depressants such as benzodiazepines and alcohol may cause additional central nervous system depressant effects such as deep sedation and respiratory depression.
If concurrent use of this drug and a central nervous system depressant is necessary, both drugs should be prescribed at the lowest effective dose for the shortest period of time, and the patient should be closely observed for signs of respiratory depression. Coadministration of this drug with CNS depressants may increase the risk of respiratory depression, hypotension, profound sedation, coma, and death due to additive effects.
- Action: Co-administration of this drug and central nervous system depressants should be prescribed only for patients for whom there is no appropriate alternative treatment method. If co-administration of this drug and a central nervous system depressant is decided, prescribe it at the lowest effective dose for the shortest period of time and closely monitor the patient for signs and symptoms of respiratory depression and sedation.
7) Warfarin
- Clinical impact: When this drug is used in combination with warfarin-like drugs, an increase in INR (International Normalized Ratio) has been reported, so prothrombin time should be evaluated regularly when medically appropriate. Post-marketing surveillance of tramadol has rarely reported changes in warfarin effects, including prothrombin time. There have been several reports suggesting that acetaminophen may cause hypoprothrombinemia when combined with warfarin-like drugs.
- Action: Monitor prothrombin time for signs of interaction in patients taking warfarin, and adjust warfarin dose if necessary.
8) Flucloxacillin
- Mechanism: Pharmacodynamic effects are additive or synergistic.
- Clinical impact: High anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis (5-oxoprolinemia) has been reported with co-administration of acetaminophen and flucloxacillin in the therapeutic dose range. Patients at the highest risk are those with underlying diseases such as sepsis, severe renal dysfunction, and malnutrition. Most patients improved after discontinuing one or both drugs.
- Action: Co-administration of acetaminophen and flucloxacillin is related to HAGMA, so caution should be exercised when taking this drug and flucloxacillin simultaneously, especially in patients with risk factors. If HAGMA is suspected, discontinue treatment with this drug and/or flucloxacillin.
9) Other
- The rate of absorption of acetaminophen may be increased with metoclopramide or domperidone and may be decreased with cholestyramine.
- When tramadol and cimetidine are administered together, there is no clinically significant change in the pharmacokinetics of tramadol.
7. Administration to children and elderly people
1) Tramadol has been shown to cross the placenta. Life-threatening respiratory depression and death have occurred in children receiving tramadol. Some reported cases occurred after tonsillectomy and/or adenoidectomy, one of whom was proven to be an ultrarapid metabolizer of tramadol (e.g., multiple copies of the cytochrome P450 isoenzyme 2D6 (CYP2D6) gene). Children with sleep apnea may be particularly sensitive to the respiratory depressant effects. The risk for life-threatening respiratory depression and death is as follows:
(1) This drug is not administered to children under 12 years of age.
(2) This drug is not administered for post-operative management to children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy.
(3) Avoid administering this drug to adolescents aged 12 to 18 years who have other risk factors that increase sensitivity to the respiratory depressant effects of tramadol, except in cases where the benefits are judged to outweigh the risks. Risk factors include conditions associated with respiratory depression, such as postoperative conditions, obstructive sleep apnea, obesity, significant pulmonary disease, neuromuscular disease, and concomitant use of other drugs that cause respiratory depression.
2) Caution should be exercised when administering this drug to elderly patients because deterioration of liver, kidney, and heart function, concurrent diseases, and various drug treatments may occur more frequently.
8. Administration to pregnant and lactating women
1) Appropriate clinical trials have not been conducted on pregnant women, and safety for the fetus has not been established. Therefore, it is administered to pregnant women or women who may be pregnant when the therapeutic benefits are judged to outweigh the risks.
The use of narcotic analgesics during childbirth may cause respiratory depression in the newborn.
Long-term use of this drug or other narcotic analgesics during pregnancy may result in neonatal abstinence syndrome, with the risk being particularly increased in the third trimester (28-40 weeks).
2) This drug should not be administered to nursing mothers. After a single intravenous administration of 100 mg of tramadol, the concentration accumulated in breast milk within 16 hours was 100 mcg of tramadol (0.1% of the nursing mother's dose) and 27 mcg of M1.
Tramadol and its active metabolite (M1) are present in breast milk. There are no data on the effects of this drug on nursing infants or breast milk production. M1 binds to the mu-opioid receptor more strongly than tramadol. Published studies have reported tramadol administration to lactating mothers in the early postpartum period and tramadol and M1 in colostrum. Women who are ultra-rapid metabolizers of tramadol may develop higher-than-expected serum M1 levels, and these higher M1 levels in breast milk may put the nursing infant at risk. In women with normal tramadol metabolism, the amount of tramadol excreted in breast milk is low and dose-dependent. Patients should be informed of the occurrence of serious adverse reactions, including excessive sedation and respiratory depression in nursing infants, during treatment with this drug.
If a nursing infant is exposed to this drug through breast milk, monitor for the development of excessive sedation and respiratory depression. Withdrawal symptoms may occur in nursing infants if the mother stops taking opioid painkillers or stops breastfeeding.
9. Effects on driving and machine operation
Tramadol may cause drowsiness or dizziness, which may be enhanced by alcohol or other central nervous system depressants. Because it affects agility, be careful when engaging in potentially dangerous activities such as driving or operating machinery.
10. Treatment in case of overdose
This drug is a combination drug. Overdosage may result in symptoms and signs of tramadol toxicity, acetaminophen toxicity, or both drugs.
1) Overdosage of tramadol may cause serious symptoms such as respiratory depression, lethargy, coma, seizures, heart attack, and death. In particular, early symptoms may include respiratory depression and/or seizures. QT prolongation has also been reported with tramadol overdose. If a child accidentally takes tramadol, respiratory depression and seizures may occur due to tramadol overdose. Respiratory depression and seizures have been reported in children who took one tablet. Deaths due to tramadol overdose have also been reported.
2) Overdosage of acetaminophen may cause centrilobular necrosis of the liver, causing liver failure and death, and tubular necrosis of the kidney, hypoglycemia, and coagulation disorders. Initial symptoms seen within the first 24 hours after an acetaminophen overdose may include abdominal discomfort, loss of appetite, nausea, vomiting, malaise, pallor, and sweating. Clinical and laboratory evidence of hepatotoxicity may not appear until 48-72 hours after administration.
3) Single or repeated overdose of this drug may be a potentially fatal combination drug overdose. In case of overdose of this drug, contact an institution or hospital that can provide emergency treatment, and ensure proper breathing is maintained along with general treatment measures. Naloxone administration can partially relieve symptoms caused by tramadol overdose, but increases the risk of seizures. In our experience with tramadol, hemodialysis is not beneficial as a treatment method for overdose, as 7% of the dose was removed after 4 hours of dialysis. In case of overdose of acetaminophen, administer N-acetylcysteine within 10-12 hours to protect the liver.
In adult and pediatric patients, those whose dose and duration of acetaminophen are unknown should have blood drawn to measure acetaminophen concentration in plasma and be treated with acetylcysteine. If the concentration of acetaminophen in plasma cannot be determined and the estimated acetaminophen dose exceeds 7.5 - 10 g for adults and adolescents or 150 mg/kg for children, N-acetylcysteine administration should be initiated and continued for the entire treatment period.
11. Others
1) In the case of tramadol, resistance has been shown in animal tests, so administer with caution in case of continuous use or increased dosage.
2) Animal and laboratory tests have not been conducted to evaluate the carcinogenicity, mutagenicity, and fertility impairment of this drug.
3) Carcinogenicity: In a carcinogenicity test in which tramadol 30mg/kg (90mg/m2, 0.5 times the maximum daily clinical dose of 185mg/m2) was orally administered to mice for 2 years, the occurrence of tumors in the lung and liver was small, but increased statistically significantly. It is believed that there is no risk of such tumors occurring in humans, and it was not observed in carcinogenicity tests in rats administered tramadol at 30 mg/kg (180 mg/m2, 1 times the maximum daily clinical dose).
4) Genotoxicity: Tramadol was negative in the reverse mutation test using microorganisms, the chromosomal aberration test using mammalian cultured cells, the HPRT gene mutation test using CHO cells, the direct method among mouse lymphoma tk+/- gene mutation tests, the micronucleus test using mice and hamsters, and the dominant lethal test using mice, but mild mutations were induced in the metabolic activation method and rat micronucleus test among mouse lymphoma gene mutation tests. Considering the overall test results, tramadol has no risk of genotoxicity in humans.
5) Fertility: In a test where tramadol was administered up to 50mg/kg (350mg/m2, 1.6 times the maximum daily clinical dose of 185mg/m2) to male rats and 75mg/kg (450mg/m2, 2.4 times the maximum daily clinical dose of 185mg/m2) to female rats, no effect on fertility was observed.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Store safely out of reach of others to reduce the risk of accidental ingestion, misuse, or abuse of the drug.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture
- Active ingredient: Tramadol hydrochloride (KP)----37.5mg
Acetaminophen (KP)----325mg
- Additives: Powdered cellulose, magnesium stearate, Opadry yellow (310B620001), corn starch, sodium starch glycolate, gelatinized starch, povidone K30
2. Effectiveness
Moderate-severe acute and chronic pain
3. Dosage and dosage
Children and adults over 12 years of age:
The dosage is adjusted according to the patient's pain level and response to treatment.
It is recommended to administer 2 tablets as the initial dose, and the interval between subsequent doses should be at least 6 hours, but should not exceed 8 tablets per day.
Administer the lowest effective dose for as short a period of time as possible.
Do not administer this drug for a longer period of time than necessary. If long-term administration is necessary due to the nature or severity of the disease, conduct regular monitoring to check whether this drug should be continued.
old man
Administer the usual adult dose. However, when tramadol is administered orally to the elderly over 75 years of age, the elimination half-life of tramadol increases by 17%, so this drug should be administered at intervals of at least 6 hours.
renal failure patient
For patients with moderate renal failure (creatinine clearance of 10-30ml/min), the administration interval should be extended to 12 hours.
Administration is not recommended for patients with severe renal failure (creatinine clearance less than 10 ml/min).
Because tramadol is eliminated very slowly during hemodialysis and filtration, there is no need to re-administer this drug to maintain the analgesic effect after dialysis.
liver failure patient
For patients with moderate liver failure, extended administration intervals should be carefully considered.
This drug should not be administered to patients with severe liver failure.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this drug, it may cause liver damage.
2) In very rare cases, serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported in patients taking acetaminophen, and these serious skin reactions can be fatal. Therefore, patients should be fully informed of the signs of such serious skin reactions, and if skin rash or other signs of hypersensitivity appear after taking this drug, they should immediately stop taking it.
3) Seizures have been reported in patients receiving tramadol within the recommended dose range, and the risk of seizures has been shown to increase when doses exceeding the recommended dose are administered.
The risk of seizures increases when tramadol is combined with the following drugs:
- Selective serotonin reuptake inhibitors (SSRI antidepressants or appetite suppressants)
- Tricyclic antidepressants (TCAs) and other tricyclic drugs (e.g. cyclobenzaprine, promethazine, etc.)
- Other drugs
Tramadol may increase the risk of seizures when combined with the following drugs:
- MAO (Monoamine Oxidase) inhibitor
- Neuroleptics
- Drugs that can lower the seizure threshold
The risk of developing convulsions may be increased in patients with epilepsy, those with a history of seizures, or those with risk factors for seizures (head injury, metabolic disorders, patients with alcohol or drug withdrawal, central nervous system infections).
4) Rarely fatal anaphylactoid reactions have been reported in patients receiving tramadol.
5) Treating patients with acute and severe bronchial asthma with narcotic analgesics increases the risk of life-threatening respiratory depression. When administering this drug to this patient group, it must be administered in a place where monitoring is possible or cardiopulmonary resuscitation equipment is available.
Caution should be exercised when administering this drug to patients at risk of respiratory depression, and use of other non-narcotic analgesics should be considered.
6) Concurrent administration of tramadol and central nervous system depressants, including alcohol or benzodiazepine drugs, may cause deep sedation, respiratory depression, coma, and death. Because of these risks, co-administration of this drug and central nervous system depressants should be prescribed only for patients for whom there are no appropriate alternative treatments. If co-administration of this drug and a central nervous system depressant is decided, prescribe it at the lowest effective dose for the shortest period of time and closely monitor the patient for signs and symptoms of respiratory depression and sedation.
7) Administration of this drug to patients with increased intracranial pressure or head injury may cause serious symptoms due to carbon dioxide retention and a secondary increase in cerebrospinal fluid pressure due to the respiratory depressant effect of narcotic analgesics.
8) Tramadol can cause mental and physical dependence of morphine type (μ-opioid).
9) Hepatotoxicity: This drug contains acetaminophen and tramadol. Acetaminophen has been associated with acute liver failure, sometimes resulting in liver transplantation and death, and most liver damage has been associated with doses exceeding 4,000 milligrams per day taken with other acetaminophen products, so use with caution. In particular, patients with liver impairment must consult with their doctor before taking this medication.
10) Patients who are CYP2D6 ultra-fast metabolizers can metabolize tramadol to its active metabolite (M1) more quickly and completely than other patients. This rapid metabolism may result in higher than expected serum M1 concentrations, which may increase the risk of respiratory depression. For patients known to be CYP2D6 ultrarapid metabolizers, alternative agents, dose reduction, and/or increased frequency of monitoring for signs of tramadol overdose (e.g., respiratory depression) are recommended. Even at the recommended dose of this drug, ultra-rapid metabolizers may experience life-threatening or fatal respiratory depression or other symptoms during overdose (see 10. Treatment in case of overdose - 1) Tramadol).
11) Ultra-rapid metabolism of tramadol and another risk factor for life-threatening respiratory depression in children: Life-threatening respiratory depression and death have occurred in children administered tramadol. Some reported cases occurred after children underwent tonsillectomy and/or adenoidectomy and were demonstrated to be ultra-rapid metabolizers of tramadol due to CYP2D6 polymorphism. This drug is not administered to children under 12 years of age and children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy. This drug should be avoided in children 12 to 18 years of age who have other risk factors that increase susceptibility to the respiratory depressant effects of tramadol.
12) This drug may cause sleep apnea syndrome (including central sleep apnea) and hypoxia (including sleep-related hypoxia), and the risk of occurrence increases in a dose-dependent manner. It is necessary to continuously evaluate whether sleep apnea occurs or existing symptoms worsen, and in this case, gradually reducing or discontinuing the drug dose should be considered.
13) Hyponatremia has been reported very rarely when using this drug, and is generally reported in patients with vulnerable risk factors such as the elderly and/or those taking drugs that may cause hyponatremia. In some reports, this hyponatremia has been shown to be the result of syndrome of dysdiuretic hormone secretion (SIADH) and is reversible with discontinuation of this drug and appropriate treatment (e.g. fluid restriction). Monitoring for signs and symptoms of hyponatremia during treatment with this drug is recommended for patients with predisposed risk factors.
2. Do not administer to the following patients
1) Patients with hypersensitivity to the ingredients of this drug
2) Patients addicted to drugs that act on the central nervous system, such as alcohol, sleeping pills, centrally acting analgesics, narcotic analgesics, or psychotropic drugs
3) Patients with severe respiratory depression (mild respiratory depression may occur)
4) Patients at risk of clouding of consciousness due to head injury or brain lesion
5) Patients receiving MAO inhibitors or patients who have taken the medication within the last 14 days
6) Patients with peptic ulcers and severe blood abnormalities
7) Patients with severe hepatic impairment, severe renal impairment, or severe cardiac dysfunction
8) Nursing mothers
9) Children under 12 years of age
10) Post-operative management in children under 18 years of age who underwent tonsillectomy and/or adenoidectomy.
11) Patients with aspirin asthma (asthma attacks caused by non-steroidal anti-inflammatory drugs) or a history of it
12) Acute and severe bronchial asthma patients in places without monitoring equipment or cardiopulmonary resuscitation equipment
13) Patients with epilepsy not controlled by medication
3. Administer with caution to the following patients:
1) Patients taking concurrent or repeated administration of morphine (a mild antagonistic effect of morphine was recognized in animal experiments, so withdrawal symptoms may occur).
2) Patients taking central nervous system depressants such as narcotic analgesics, anesthetics, hypnotics, phenothiazines, tranquilizers, sedatives, etc.
3) Patients with biliary disease (in animal experiments, when administered in large quantities, the sphincter of Oddi contracted.)
4) Patients with hepatic impairment (in animal experiments, serum GOT and GPT activity levels may be elevated.)
5) Patients with renal impairment
6) Drunk patient
7) Patients with hypersensitivity to narcotic analgesics
8) Patients with epilepsy or those likely to have seizures
9) Patients in shock or changes in consciousness due to unknown causes
4. Adverse reactions
4.1 Clinical trial data
1) Adverse reactions reported at a rate of more than 1% in the group administered this drug during placebo-controlled clinical trials of this drug
* Refer to manual for table details
2) Adverse reactions reported at a rate of less than 1% in the group administered this drug during placebo-controlled clinical trials of this drug
* Refer to manual for table details
3) Adverse reactions confirmed in clinical trials/post-marketing surveillance of tramadol
* Refer to manual for table details
4) Regarding adverse reactions identified in clinical trials/post-marketing surveillance of acetaminophen, allergic reactions (mainly skin rash) or secondary hypersensitivity reactions to acetaminophen were rarely reported, but generally recovered after discontinuation of drug administration, and symptomatic treatment was administered when necessary. Blood disorders, including thrombocytopenia and agranulocytosis, have been reported but not necessarily related to acetaminophen. There are several reports indicating that acetaminophen may cause hypoprothrombinemia when administered together with warfarin analogues. Cases of metabolic acidosis due to pyroglutamic acidosis (HAGMA) have been reported in patients with risk factors who use acetaminophen.
4.2. Adverse reactions after marketing
1) The following post-marketing adverse reactions were confirmed: hyponatremia/antidiuretic hormone secretion syndrome, fixed eruption.
2) As a result of a post-marketing survey conducted on 37,967 patients over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 4.57% (1,737/37,967, 2,501 cases) regardless of causal relationship with the drug. The most common adverse reactions were digestive system adverse reactions such as nausea, constipation, and vomiting (1,391 cases (3.66%)), nervous system adverse events such as dizziness and headache (563 cases (1.48%)), systemic abnormalities (149 cases (0.39%)), mental abnormalities (149 cases (0.39%)), skin and appendages (105 cases (0.28%)), and blood system adverse reactions (105 cases). 31 cases (0.08%), kidney and urinary system 28 cases (0.07%), circulatory system 28 cases (0.07%), respiratory system 21 cases (0.06%), cardiovascular system 1 case and other 43 cases (0.11%).
The incidence of adverse drug reactions for which a causal relationship with this drug could not be ruled out was 4.14% (1,573 people/37,967 people, 2,244 cases). The main adverse drug reactions are nausea 1.49% (567 people/37,967 people) and dizziness 0.95% (358 people/37,967 people). Other adverse reactions reported in less than 1% are classified by institution as follows.
(1) Systemic abnormalities: asthenia, fatigue, fever, edema, chest pain, stiffness, syncope
(2) Cardiovascular system: congestive heart failure
(3) Nervous system: Dizziness, headache, vertigo, stupor, migraine, tremor, paresthesia, hypertonia, worsening migraine, involuntary muscle contraction, convulsions.
(4) Respiratory system: dyspnea, asthma, dyspnea on exertion, cough, bronchitis
(5) Kidney and urinary system: urinary disorders, urinary retention, frequent urination, abnormal kidney function levels, oliguria
(6) Skin and appendages: pruritus, rash, increased sweating, urticaria
(7) Digestive system: nausea, vomiting, indigestion, abdominal pain, constipation, dry mouth, diarrhea, dysphagia, fart, tongue edema, increased saliva, rectal cancer progression, esophageal cancer progression, stomach cancer progression, paralytic ileus, hiccups, cholecystitis
(8) Mental system: drowsiness, insomnia, loss of appetite, anxiety, depression, nervousness, emotional instability, hallucinations, depersonalization
(9) Blood system: anemia, decreased hemoglobin, decreased red blood cells, decreased white blood cells, increased white blood cells, decreased platelets
(10) Circulatory system: palpitations, hypertension, arrhythmia, tachycardia, worsening hypertension, aortic stenosis
(11) Others: bleeding, increased cholesterol, weight loss, tinnitus, chills, buttock pain, thigh pain, allergic rhinitis, epistaxis, abnormal vision, progression of biliary tract cancer, foreign body sensation in the eyes, progression of liver cancer, abnormal liver function
Serious adverse drug reactions included one case each of liver dysfunction, cholecystitis, paralytic ileus, and stupor, and one case each of unexpected drug adverse reactions included cholecystitis, hiccups, paralytic ileus, abnormal kidney function levels (elevated BUN/CR), increased saliva, and bleeding.
In a survey targeting patients with renal impairment, a special type of patient, the occurrence rate of adverse drug reactions was 6.25% (11/176, 165 cases), and the main adverse drug reactions were nausea and dizziness, 4 cases each (2.27%). There were no serious adverse drug reactions or unexpected adverse reactions. In a survey targeting patients with liver impairment, a special type of patient, the incidence of adverse drug reactions was 6.63% (22/332, 36 cases), and the main adverse drug reactions were nausea in 12 cases (3.61%) and dizziness in 6 cases (1.81%). The serious adverse drug reactions were one case each of paralytic ileus, cholecystitis, and liver dysfunction (0.30%), and the unexpected adverse reactions were one case each of paralytic ileus and cholecystitis.
3) Serious adverse reactions reported voluntarily during the domestic post-marketing surveillance period were 3 cases of nausea, 2 cases each of vertigo and dyspnea, stupor, migraine, speech impediment, loss of consciousness, recurrence of myocardial infarction, hypotension, vomiting, dyspepsia, confusion, multiple organ failure, anaphylaxis, and intentional overdose, for a total of 23 cases. Since these were reported from a population of uncertain size, the frequency and causal relationship of this drug must be confirmed. It's difficult to estimate.
4) In addition, during the domestic post-marketing surveillance period, as a result of a separate post-marketing clinical trial conducted on a total of 5,566 people in addition to the use result survey, a total of 3 cases of unexpected adverse drug reactions were reported, 2 cases of belching (0.04%) and 1 case of chest discomfort (0.02%).
5) Patients who had a history of taking therapeutic drugs (painkillers) before administering this drug had a statistically significantly higher rate of adverse reactions compared to those who had no history of taking medication (5.92% vs 3.75%, p<0.001)). In addition, the adverse reaction rate in the subjects of investigation whose average daily dose was 4 or more tablets was 8.35% (289/3460 people), which was statistically significantly higher than the 4.36% (1325/30419 people) in the patient group who took 2 or more but less than 4 tablets (p<0.001).
5. General precautions
1) Do not administer in excess of the recommended dose, and do not administer in combination with other tramadol or acetaminophen products.
2) This medicine contains tramadol as its main ingredient. Part of the analgesic effect of this drug is due to the binding of tramadol, the main ingredient of this drug, to mu-opioid receptors. Repeated administration of narcotic analgesics, even at recommended doses, may result in intolerance, physical dependence, and psychological dependence. Before prescribing this medication, the patient's risk for dependence and abuse of opioids should be assessed, and all patients receiving this medication should be monitored for the development of such behaviors. The risk is increased in patients with a history or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). This drug should not be used in patients dependent on narcotic analgesics. In some patients who were previously dependent on other narcotic analgesics, tramadol has been associated with relapse of physical dependence. Patients at risk of drug abuse or dependence should be observed carefully and administered for a short period of time. Tramadol is not appropriate as an alternative medication for patients dependent on narcotic analgesics and does not suppress the withdrawal symptoms of opiate drugs or morphine. Concomitant use with opioid agonists-antagonists (nalbuphine, buprenorphine, pentazocine) is not recommended because there is a risk of reduced analgesic effect and withdrawal symptoms due to competitive blocking effect at the receptor.
3) If you suddenly stop taking this drug, withdrawal symptoms such as anxiety, sweating, insomnia, stiffness, pain, nausea, tremor, diarrhea, upper respiratory syndrome, piloerection, excitement, nervousness, hyperkinesia, and gastrointestinal symptoms may appear. Panic attacks, severe anxiety, hallucinations, paresthesias, tinnitus, and abnormal central nervous system reactions have also been reported very rarely. Clinical experience shows that withdrawal symptoms can be alleviated if the drug dose is reduced and discontinued.
4) In patients receiving tramadol, allergic reactions such as urticaria, rash, bronchospasm, toxic skin necrosis, and Stevenson-Johnson syndrome, including rare but serious and fatal anaphylactic reactions, have been reported. This drug should not be administered to patients with a history of anaphylactoid reactions to codeine and other narcotic analgesics because the risk may be increased. Patients are advised to seek medical help immediately if symptoms of hypersensitivity appear.
5) Convulsions have been reported when tramadol is administered to patients taking other drugs with the potential for seizures or lowering the seizure threshold, especially selective serotonin reuptake inhibitors, tricyclic antidepressants, antipsychotics, centrally acting analgesics, or local anesthetics. Patients with epilepsy controlled with medication or patients with the possibility of epilepsy should be administered this drug only when absolutely necessary.
6) Excessive acetaminophen administration to chronic alcoholics may increase liver toxicity. Administration of this drug to patients with hepatic impairment is not recommended.
7) The pharmacokinetics and tolerability of this drug have not been tested in patients with liver dysfunction. Tramadol and acetaminophen are metabolized primarily in the liver. Patients with severe hepatic impairment are not recommended to use this drug.
8) The combination of tramadol and acetaminophen has not been tested in patients with renal failure. Experience with the use of tramadol may reduce the extent and rate of excretion of tramadol and its active metabolite M1 in patients with renal insufficiency. For patients with a creatinine clearance of less than 30 mL/min, the dosing interval should not exceed 2 tablets every 12 hours.
9) When tramadol is administered long-term, it is difficult to completely exclude the possibility of dependence, so the administration period must be adjusted or a temporary withdrawal period must be taken.
10) In one study, it was reported that when tramadol was used during general anesthesia with enfluorene and nitric oxide, the number of cases of anesthesia weakening during surgery increased. Until further information is available, use of tramadol during mild-level anesthesia should be avoided.
11) Caution should be exercised when administering this drug to patients taking selective serotonin reuptake inhibitors. The risk of adverse reactions, including seizures and serotonin syndrome, increases when tramadol is combined with selective serotonin reuptake inhibitors.
12) Life-threatening respiratory depression and death occurred in children administered tramadol. Tramadol and codeine are subject to metabolic variability based on CYP2D6 genotype, which may increase exposure to active metabolites. Post-marketing reports on tramadol or codeine suggest that children under 12 years of age may be susceptible to the respiratory depressant effects of tramadol. Children with obstructive sleep apnea who are treated with opioids for pain, especially after tonsillectomy and/or adenoidectomy, may be sensitive to respiratory depressant effects. The risk for life-threatening respiratory depression and death is as follows:
(1) This drug is not administered to children under 12 years of age.
(2) This drug is not administered for post-operative management to children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy.
(3) Avoid administering this drug to adolescents aged 12 to 18 years who have other risk factors that increase sensitivity to the respiratory depressant effects of tramadol, except in cases where the benefits are judged to outweigh the risks. Risk factors include conditions associated with respiratory depression, such as postoperative conditions, obstructive sleep apnea, obesity, significant pulmonary disease, neuromuscular disease, and concomitant use of other drugs that cause respiratory depression.
(4) When prescribing opioids to children, like adults, health care professionals should administer the lowest effective dose for the shortest period of time and inform patients, guardians, and caregivers about the symptoms and risks of opioid overdose.
13) Serious, life-threatening, or fatal cases in patients receiving recommended doses of tramadol.
Respiratory depression has been reported. If it is not recognized and treated promptly, it may lead to respiratory arrest and death. Management may include close observation of associated symptoms and the use of an opioid antagonist; symptoms should be treated appropriately according to the patient’s clinical condition. Carbon dioxide retention caused by respiratory depression after taking this medicine may intensify signs and symptoms of sedation.
14) Tramadol is subject to polymorphic metabolism, like codeine, in ultra-rapid metabolizers of CYP2D6 substrates exposed to potentially life-threatening levels of M1. At least one death has been reported in a nursing infant exposed to high levels of morphine in breast milk due to the mother being an extremely rapid metabolizer of codeine. Nursing infants whose mothers were ultrarapid metabolizers who administered this drug may have been exposed to potentially high levels of M1 and experienced life-threatening respiratory depression.
15) Opioid analgesics can sometimes cause reversible adrenal insufficiency requiring careful monitoring and glucocorticoid replacement therapy. Symptoms of acute or chronic adrenal insufficiency include severe abdominal pain, nausea, vomiting, low blood pressure, extreme fatigue, loss of appetite, and weight loss.
15) This drug may cause opioid-induced hyperalgesia. Symptoms of opioid-induced hyperalgesia include, but are not limited to, increased pain levels with dose increases, decreased pain levels with dose decreases, or pain from stimuli that do not normally cause pain. If a patient develops these symptoms, a dose reduction or change in opioid should be carefully considered.
6. Drug interactions
1) MAO inhibitors (e.g. phenelzine, tranylcypromine, linezolid)
- Mechanism: Drug effects are additive or synergistic.
- Clinical implications: Co-administration of this drug in patients receiving MAO inhibitors or who have taken such drugs within the past 14 days should be contraindicated due to the increased risk of seizures and serotonin syndrome. (Refer to 2. Do not administer to the following patients). Interaction of MAO inhibitors with opioids may result in serotonin syndrome or opioid toxicity.
- Action: Patients who are taking MAO inhibitors or have stopped taking them within 14 days should not use this drug.
2) Serotonergic drugs (e.g. selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptophan, 5-HT3 receptor antagonists, mirtazapine, trazodone, drugs that affect the serotonergic neurotransmission system, cyclobenzaprine, metaxalone back skeletal muscle relaxant)
- Mechanism: Drug effects are additive or synergistic.
- Clinical implications: Combination use of tramadol and serotonergic drugs increases the risk of adverse events, including seizures and serotonin syndrome.
- Measures: When administering this drug to patients taking serotonergic drugs, monitor for signs of adverse reactions and exercise caution. If serotonin syndrome is suspected, discontinue treatment with this drug.
3) CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin)
- Mechanism: CYP3A4 induction increases the metabolic rate of tramadol.
- Clinical Effects: When this drug is co-administered with a CYP3A4 inducer, the blood concentration of tramadol may decrease, which may result in decreased therapeutic effect or development of withdrawal symptoms in patients who are physically dependent on tramadol. After discontinuation of CYP3A4 inducer administration, the effect decreases and blood tramadol concentration increases. This may increase or prolong the therapeutic effect and adverse reactions, and may result in severe respiratory depression, seizures, and serotonin syndrome.
- Action: If co-administration of this drug and a CYP3A4 inducer is necessary, consider increasing the dose of this drug until stable drug effects are achieved.
Monitor patients for signs of opioid withdrawal. If treatment with a CYP3A4 inducer is discontinued, consider reducing the dose and monitor the patient for signs of seizures, serotonin syndrome, sedation, and respiratory depression. When used in combination with carbamazepine, the analgesic effect and duration of action of tramadol may be significantly reduced due to a decrease in the plasma concentration of tramadol. Coadministration is not recommended because carbamazepine increases tramadol metabolism and may increase the risk of tramadol seizures.
4) CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine, amitriptyline, bupropion)
- Mechanism: CYP2D6 inhibition reduces the metabolic rate of tramadol.
- Clinical effects: When this drug is co-administered with a CYP2D6 inhibitor, especially when a CYP2D6 inhibitor is added after a stable dose of this drug is reached, the blood concentration of tramadol may increase and the blood concentration of the metabolite M1 may decrease. Because M1 is a more potent mu-opioid agonist, reduced M1 exposure may reduce therapeutic efficacy in patients with physical dependence to tramadol and may result in signs and symptoms of opioid withdrawal. Increased exposure to tramadol may increase or prolong the therapeutic effect and may increase the risk of serious adverse events such as seizures and serotonin syndrome. After discontinuation of CYP2D6 inhibitor administration, the effect decreases, so the blood tramadol concentration decreases and the blood M1 concentration increases. While this may increase or prolong the therapeutic effect, it may also increase adverse reactions related to opioid toxicity and may potentially cause fatal respiratory depression.
- Action: If co-administration of this drug and a CYP2D6 inhibitor is necessary, closely observe patients for adverse reactions such as opioid withdrawal, seizures, and serotonin syndrome. When treatment with a CYP2D6 inhibitor is discontinued, consider reducing the dose until stable drug effects are achieved. Monitor patients closely for adverse events such as respiratory depression and sedation.
5) CYP3A4 inhibitors (e.g. macrolide antibiotics such as erythromycin, azole antifungals such as ketoconazole, protease inhibitors such as ritonavir)
- Mechanism: CYP3A4 inhibition reduces the metabolic rate of tramadol.
- Clinical implications: Co-administration of this drug with CYP3A4 inhibitors may increase blood concentrations of tramadol and may increase metabolism through CYP2D6 and blood concentrations of M1. After discontinuation of CYP3A4 inhibitors, their effectiveness decreases and blood tramadol concentrations decrease. This may reduce the effects of the opioid and reduce signs and symptoms of opioid withdrawal in patients with physical dependence on tramadol.
- Action: If co-administration of this drug and a CYP3A4 inhibitor is necessary, consider reducing the dose of this drug until stable drug effects are achieved. In particular, when a CYP3A4 inhibitor is added when a stable dose of this drug is reached, patients should be closely monitored for an increased risk of adverse reactions related to opioid toxicity, such as seizures, severe adverse events such as serotonin syndrome, and potentially fatal respiratory depression.
If the CYP3A4 inhibitor is discontinued, consider increasing the dose until stable drug effects are achieved, and monitor the patient for signs and symptoms of opioid withdrawal.
6) Central nervous system depressants such as benzodiazepines and alcohol (e.g. benzodiazepines and other sedative/hypnotics, tranquilizers, muscle relaxants, general anesthetics, other opioids, alcohol)
- Mechanism: Drug effects are additive or synergistic.
- Clinical effects: Concurrent administration of tramadol with central nervous system depressants such as benzodiazepines and alcohol may cause additional central nervous system depressant effects such as deep sedation and respiratory depression.
If concurrent use of this drug and a central nervous system depressant is necessary, both drugs should be prescribed at the lowest effective dose for the shortest period of time, and the patient should be closely observed for signs of respiratory depression. Coadministration of this drug with CNS depressants may increase the risk of respiratory depression, hypotension, profound sedation, coma, and death due to additive effects.
- Action: Co-administration of this drug and central nervous system depressants should be prescribed only for patients for whom there is no appropriate alternative treatment method. If co-administration of this drug and a central nervous system depressant is decided, prescribe it at the lowest effective dose for the shortest period of time and closely monitor the patient for signs and symptoms of respiratory depression and sedation.
7) Warfarin
- Clinical impact: When this drug is used in combination with warfarin-like drugs, an increase in INR (International Normalized Ratio) has been reported, so prothrombin time should be evaluated regularly when medically appropriate. Post-marketing surveillance of tramadol has rarely reported changes in warfarin effects, including prothrombin time. There have been several reports suggesting that acetaminophen may cause hypoprothrombinemia when combined with warfarin-like drugs.
- Action: Monitor prothrombin time for signs of interaction in patients taking warfarin, and adjust warfarin dose if necessary.
8) Flucloxacillin
- Mechanism: Pharmacodynamic effects are additive or synergistic.
- Clinical impact: High anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis (5-oxoprolinemia) has been reported with co-administration of acetaminophen and flucloxacillin in the therapeutic dose range. Patients at the highest risk are those with underlying diseases such as sepsis, severe renal dysfunction, and malnutrition. Most patients improved after discontinuing one or both drugs.
- Action: Co-administration of acetaminophen and flucloxacillin is related to HAGMA, so caution should be exercised when taking this drug and flucloxacillin simultaneously, especially in patients with risk factors. If HAGMA is suspected, discontinue treatment with this drug and/or flucloxacillin.
9) Other
- The rate of absorption of acetaminophen may be increased with metoclopramide or domperidone and may be decreased with cholestyramine.
- When tramadol and cimetidine are administered together, there is no clinically significant change in the pharmacokinetics of tramadol.
7. Administration to children and elderly people
1) Tramadol has been shown to cross the placenta. Life-threatening respiratory depression and death have occurred in children receiving tramadol. Some reported cases occurred after tonsillectomy and/or adenoidectomy, one of whom was proven to be an ultrarapid metabolizer of tramadol (e.g., multiple copies of the cytochrome P450 isoenzyme 2D6 (CYP2D6) gene). Children with sleep apnea may be particularly sensitive to the respiratory depressant effects. The risk for life-threatening respiratory depression and death is as follows:
(1) This drug is not administered to children under 12 years of age.
(2) This drug is not administered for post-operative management to children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy.
(3) Avoid administering this drug to adolescents aged 12 to 18 years who have other risk factors that increase sensitivity to the respiratory depressant effects of tramadol, except in cases where the benefits are judged to outweigh the risks. Risk factors include conditions associated with respiratory depression, such as postoperative conditions, obstructive sleep apnea, obesity, significant pulmonary disease, neuromuscular disease, and concomitant use of other drugs that cause respiratory depression.
2) Caution should be exercised when administering this drug to elderly patients because deterioration of liver, kidney, and heart function, concurrent diseases, and various drug treatments may occur more frequently.
8. Administration to pregnant and lactating women
1) Appropriate clinical trials have not been conducted on pregnant women, and safety for the fetus has not been established. Therefore, it is administered to pregnant women or women who may be pregnant when the therapeutic benefits are judged to outweigh the risks.
The use of narcotic analgesics during childbirth may cause respiratory depression in the newborn.
Long-term use of this drug or other narcotic analgesics during pregnancy may result in neonatal abstinence syndrome, with the risk being particularly increased in the third trimester (28-40 weeks).
2) This drug should not be administered to nursing mothers. After a single intravenous administration of 100 mg of tramadol, the concentration accumulated in breast milk within 16 hours was 100 mcg of tramadol (0.1% of the nursing mother's dose) and 27 mcg of M1.
Tramadol and its active metabolite (M1) are present in breast milk. There are no data on the effects of this drug on nursing infants or breast milk production. M1 binds to the mu-opioid receptor more strongly than tramadol. Published studies have reported tramadol administration to lactating mothers in the early postpartum period and tramadol and M1 in colostrum. Women who are ultra-rapid metabolizers of tramadol may develop higher-than-expected serum M1 levels, and these higher M1 levels in breast milk may put the nursing infant at risk. In women with normal tramadol metabolism, the amount of tramadol excreted in breast milk is low and dose-dependent. Patients should be informed of the occurrence of serious adverse reactions, including excessive sedation and respiratory depression in nursing infants, during treatment with this drug.
If a nursing infant is exposed to this drug through breast milk, monitor for the development of excessive sedation and respiratory depression. Withdrawal symptoms may occur in nursing infants if the mother stops taking opioid painkillers or stops breastfeeding.
9. Effects on driving and machine operation
Tramadol may cause drowsiness or dizziness, which may be enhanced by alcohol or other central nervous system depressants. Because it affects agility, be careful when engaging in potentially dangerous activities such as driving or operating machinery.
10. Treatment in case of overdose
This drug is a combination drug. Overdosage may result in symptoms and signs of tramadol toxicity, acetaminophen toxicity, or both drugs.
1) Overdosage of tramadol may cause serious symptoms such as respiratory depression, lethargy, coma, seizures, heart attack, and death. In particular, early symptoms may include respiratory depression and/or seizures. QT prolongation has also been reported with tramadol overdose. If a child accidentally takes tramadol, respiratory depression and seizures may occur due to tramadol overdose. Respiratory depression and seizures have been reported in children who took one tablet. Deaths due to tramadol overdose have also been reported.
2) Overdosage of acetaminophen may cause centrilobular necrosis of the liver, causing liver failure and death, and tubular necrosis of the kidney, hypoglycemia, and coagulation disorders. Initial symptoms seen within the first 24 hours after an acetaminophen overdose may include abdominal discomfort, loss of appetite, nausea, vomiting, malaise, pallor, and sweating. Clinical and laboratory evidence of hepatotoxicity may not appear until 48-72 hours after administration.
3) Single or repeated overdose of this drug may be a potentially fatal combination drug overdose. In case of overdose of this drug, contact an institution or hospital that can provide emergency treatment, and ensure proper breathing is maintained along with general treatment measures. Naloxone administration can partially relieve symptoms caused by tramadol overdose, but increases the risk of seizures. In our experience with tramadol, hemodialysis is not beneficial as a treatment method for overdose, as 7% of the dose was removed after 4 hours of dialysis. In case of overdose of acetaminophen, administer N-acetylcysteine within 10-12 hours to protect the liver.
In adult and pediatric patients, those whose dose and duration of acetaminophen are unknown should have blood drawn to measure acetaminophen concentration in plasma and be treated with acetylcysteine. If the concentration of acetaminophen in plasma cannot be determined and the estimated acetaminophen dose exceeds 7.5 - 10 g for adults and adolescents or 150 mg/kg for children, N-acetylcysteine administration should be initiated and continued for the entire treatment period.
11. Others
1) In the case of tramadol, resistance has been shown in animal tests, so administer with caution in case of continuous use or increased dosage.
2) Animal and laboratory tests have not been conducted to evaluate the carcinogenicity, mutagenicity, and fertility impairment of this drug.
3) Carcinogenicity: In a carcinogenicity test in which tramadol 30mg/kg (90mg/m2, 0.5 times the maximum daily clinical dose of 185mg/m2) was orally administered to mice for 2 years, the occurrence of tumors in the lung and liver was small, but increased statistically significantly. It is believed that there is no risk of such tumors occurring in humans, and it was not observed in carcinogenicity tests in rats administered tramadol at 30 mg/kg (180 mg/m2, 1 times the maximum daily clinical dose).
4) Genotoxicity: Tramadol was negative in the reverse mutation test using microorganisms, the chromosomal aberration test using mammalian cultured cells, the HPRT gene mutation test using CHO cells, the direct method among mouse lymphoma tk+/- gene mutation tests, the micronucleus test using mice and hamsters, and the dominant lethal test using mice, but mild mutations were induced in the metabolic activation method and rat micronucleus test among mouse lymphoma gene mutation tests. Considering the overall test results, tramadol has no risk of genotoxicity in humans.
5) Fertility: In a test where tramadol was administered up to 50mg/kg (350mg/m2, 1.6 times the maximum daily clinical dose of 185mg/m2) to male rats and 75mg/kg (450mg/m2, 2.4 times the maximum daily clinical dose of 185mg/m2) to female rats, no effect on fertility was observed.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Store safely out of reach of others to reduce the risk of accidental ingestion, misuse, or abuse of the drug.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 9items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 9 | Megaspen Tab. | Precautions for use | 2026.02.19 | PDF0103_200804802_Precautions for use_Megaspen tablet_Modified.pdf |
| 8 | Megaspen Tab. | Precautions for use | 2025.11.10 | PDFPrecautions for using Megaspen tablets.pdf |
| 7 | Megaspen Tab. | Precautions for use | 2025.03.20 | PDF0104_200804802_Precautions for use_Megasphen tablet.pdf |
| 6 | Megaspen Tab. | Precautions for use | 2024.10.02 | PDFMegaspen Tablet_Change Plan + Change Comparison Table.pdf |
| 5 | Megaspen Tab. | Precautions for use | 2021.12.28 | Change plan + change comparison table (precautions for use)_MegaSpen Tablet.pdfFile under review |
| 4 | Megaspen Tab. | Dosage, usage precautions | 2021.02.18 | HWPContents of permission change order_acetaminophen, tramadol hydrochloride complex (tablets).hwp |
| 3 | Megaspen Tab. | Megaspen tablets (dosage, instructions, precautions for use) | 2018.03.09 | PDFTramadol hydrochloride + acetaminophen + combination film-coated tablet + container |
| 2 | Megaspen Tab. | Megaspen tablets (precautions for use) | 2011.04.11 | HWPMegaspen tablets (precautions for use).hwp |
| 1 | Megaspen Tab. | Megaspen tablets (precautions for use) | 2009.05.22 | HWP9. Change order for permission (Megaspen Tablet)(2009.05.22).hwp |